Zhiwei Sun

Title: Zhiwei Sun: Innovator in Antibody Development

Introduction

Zhiwei Sun is a prominent inventor based in Beijing, China. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for medical applications. His innovative work focuses on creating targeted therapies for diseases such as cancer and autoimmune disorders.

Latest Patents

Zhiwei Sun holds a patent for a "Human anti-human epidermal growth factor receptor antibody and encoding gene and application thereof." This invention provides human anti-human epidermal growth factor receptor (EGFR) antibodies and their encoding genes. By utilizing gene engineering techniques and phage surface display technology, he successfully screens anti-human EGFR gene engineering single chain antibodies from a fully synthetic single chain human antibody library. The resulting antibody variable gene sequence allows for the construction of intact human monoclonal antibodies, leading to the production of high-purity antibody proteins. The binding affinity of these antibodies with human EGFR is no more than 1 nM, demonstrating their potential effectiveness in inhibiting tumor growth in EGFR-expressing cell models.

Career Highlights

Zhiwei Sun is currently associated with Shanghai Saiyuan Bio-technology Co., Ltd., where he continues to advance his research in antibody development. His work has significant implications for the treatment of EGFR-targeted tumors and other diseases, including inflammation and autoimmune conditions.

Collaborations

Zhiwei Sun collaborates with Shuang Hong Wang, contributing to the advancement of their shared research goals in biotechnology.

Conclusion

Zhiwei Sun's innovative work in the field of antibody development showcases his commitment to improving medical treatments through biotechnology. His contributions are paving the way for new therapeutic options for patients suffering from various diseases.